About Nia Therapeutics

Restoring memory to rebuild lives

Nia TX TIMELINE
Our scientific and technological milestones

2003-2014

Developed foundational scientific work describing brain signals underlying human memory function.

2014

DARPA Restoring Active Memory project begins at the University of Pennsylvania, to develop a personalized brain stimulation therapy.

2018

First demonstration of personalized neurostimulation to improve human memory, using an externalized prototype system.

2018

Nia Therapeutics is founded and licenses patented algorithms from the University of Pennsylvania.

2019

Nia acquires patented ASIC technology for brain sensing and stimulation.

2023

First demonstration of improved memory performance in patients with a history of TBI.

2024

First successful preclinical demonstration of the SNS device in sheep.

2003-2014

Developed foundational scientific work describing brain signals underlying human memory function.

2014

DARPA Restoring Active Memory project begins at the University of Pennsylvania, to develop a personalized brain stimulation therapy.

2018

First demonstration of personalized neurostimulation to improve human memory.

2018

Nia Therapeutics is founded and licenses patented algorithms from the University of Pennsylvania.

2019

Nia acquires patented ASIC technology for brain sensing and stimulation.

2023

First demonstration of improved memory performance in patients with a history of TBI.

2024

First successful preclinical demonstration of the SNS device in sheep.

2003-2014

Developed foundational scientific work describing brain signals underlying human memory function.

2014

DARPA Restoring Active Memory project begins at the University of Pennsylvania, to develop a personalized brain stimulation therapy.

2018

First demonstration of personalized neurostimulation to improve human memory.

2018

Nia Therapeutics is founded and licenses patented algorithms from the University of Pennsylvania.

2019

Nia acquires patented ASIC technology for brain sensing and stimulation.

2023

First demonstration of improved memory performance in patients with a history of TBI.

2024

First successful preclinical demonstration of the SNS device in sheep.

Leadership Team

Our leadership team brings together the world’s foremost scientists in memory with incredible engineers and clinicians.
Dr. Michael Kahana
Founder and CEO
Dr. Mike Kahana is a pioneer in the field of human memory, with over 230 publications and over 35k citations across his three decade long career (h-index=100). He is the co-founder of the Computational Memory Lab at the University of Pennsylvania, where he is also an Edmund & Louise Kahn Term Professor of Psychology. He has been the recipient of several notable awards including the Troland Award from the National Academy of Sciences, the Psychonomic Society's Mid-Career Award, the Howard Crosby Warren Medal, and the Grossman Award. He is a co-inventor of Nia Therapeutics’ core SNS technology and brings his expertise as a foremost expert in human memory to guide Nia as its CEO.
Dr. Daniel Rizzuto
Founder, President and CTO
Dr. Dan Rizzuto has dedicated his career to developing advanced neurostimulation devices. Following his Ph.D. in Neuroscience from Brandeis University and postdoctoral training in Neural Engineering at Caltech, he served as the Director of Cognitive Neuromodulation at the University of Pennsylvania. He has also held various product development roles at Northstar Neuroscience, Varian Medical Systems, the Swedish Neuroscience Institute and the Allen Institute for Brain Science. Dr. Rizzuto is a co-inventor of Nia’s core technology and applies his product development experience to drive Nia’s technical and scientific advancements.
Daniel Utin
Chief Software Architect
Daniel is a serial entrepreneur with deep technical expertise. He has previously co-founded Cambridge Interactive Development Corporation (CIDC) and WorldWinner.com, driving R&D and leading both companies to successful exits. He has also led numerous initiatives and yielded multiple patents through his work as a Cybersecurity Researcher at the MIT Lincoln Laboratory. At Nia Therapeutics, he has led the translation of University of Pennsylvania research into a memory treatment platform that can drive clinical and commercial success.
Chuck Vadala
Senior Director, Quality & Systems Engineering
Chuck is a medical device development leader with a proven track record of bringing Class II and Class III devices to market. As a leader at medical technology companies like Insulet, CSA Medical, Heartware, Covidien and Omnisonics Medical Technologies he has directed product innovation, navigated regulatory approval and grown robust engineering teams. At Nia Therapeutics, he applies his domain expertise to attain successful regulatory milestones.
Chris Ho
Principal Software Engineer
Dr. Zhe Hu
Principal Electrical Engineer
Andrew Smiles
Senior Biomedical Engineer
Josh Kahn
Senior Firmware Engineer
Keith Angelino
Senior Mechanical Engineer
Archer Li
System Validation and Verification Engineer
Tzvi Bessler
Manager, Strategic Finance and Business Operations

Advisors

Leading medical, scientific and engineering experts guide our growth.
MEDICAL ADVISORS
Ramon Diaz-Arrastia, MD, Ph.D.
Presidential Professor of Neurology, University of Pennsylvania, Director of Traumatic Brain Injury Research Center
Bob Gross, MD, Ph.D.
Presidential Professor and Chairman of Neurosurgery, Rutgers University
Brad Lega, MD
William Kemp Clark Chair of Neurological Surgery, U.T. Southwestern
Geoff Aguirre, MD, Ph.D.
Professor of Cognitive Neurology, University of Pennsylvania
INDUSTRY ADVISORS
Milton Morris, Ph.D., MBA
NACD.DC, Former CEO and President Neuspera Medical
Independent Board Director
Bob Greenberg, MD, Ph.D.
CEO and Chairman, huMannity
Independent Board Director
Tim Marjenin, BSE
VP of Regulatory Affairs at MCRA; former FDA Branch Chief for Neurological Devices
Independent Board Director
Sat Pannu, Ph.D.
VP of Product Research and Emerging Indications, Nevro Co.
Independent Board Director

Join us

Work with us to build groundbreaking neurotechnology and aim to create a future where no human suffers from memory loss.